From today’s laborious compliance activity destined for heavy streamlining, to a proactive champion of patient priorities, a liberated pharmacovigilance function could play a much more strategically important role in drug development – and it must, says Lucinda Smith of ArisGlobal.
At the beginning of the decade, the role of drug safety attracted unprecedented mainstream attention. That was as the pandemic took hold, and as pioneering COVID-19 vaccines entered the market – and a raft of diverse treatments was applied – in the hope of virus containment and mass-scale symptom relief.
Suddenly, whole generations gained a first-hand appreciation of side-effects at scale – and of the fundamental assumption that the products they take are safe.
Check out the rest of the feature here
